An AT1 receptor antagonist
Related Products
Labeled Version(s)
25226Valsartan-d9
Metabolite(s)
278494-hydroxy Valsartan
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Valsartan

Item No. 14178

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
N-(1-oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine
CAS Number
137862-53-4
Synonyms
  • CGP 48933
Molecular Formula
C24H29N5O3
Formula Weight
435.5
Purity
≥98%
Formulation
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 30 mg/mlDMSO: 30 mg/mlEthanol: 30 mg/mlEthanol:PBS(pH 7.2) (1:1): 0.5 mg/ml
SMILES
O=C(CCCC)N([C@@](C(O)=O)([H])C(C)C)CC1=CC=C(C2=CC=CC=C2C3=NNN=N3)C=C1
InChi Code
InChI=1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m0/s1
InChi Key
ACWBQPMHZXGDFX-QFIPXVFZSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    10 mg

    $49

    Add

    25 mg

    $115

    Add

    50 mg

    $213

    Add

    100 mg

    $376

    Add
    Product Description

    Valsartan is a nonpeptide angiotensin II receptor antagonist of the angiotensin II type 1 (AT1) receptor (IC50 = 2.7 nM).1 It is 20,000-fold selective for AT1 over AT2 and, unlike some other AT receptor antagonists, does not alter peroxisome proliferator-activated receptor γ (PPARγ) activity in vitro.2 In vivo, valsartan (30 mg/kg) increases cardiac output and reduces left ventricular fibrosis in a model of heart failure with reduced ejection fraction in mice with streptozotocin-induced diabetes.3 Formulations containing valsartan have been used in the treatment of hypertension and heart failure.2,4,5

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Burnier, M. Angiotensin II type 1 receptor blockers. Circulation 103(6), 904-912 (2001).

    2. Munger, M.A. Use of angiotensin receptor blockers in cardiovascular protection: Current evidence and future directions. PT 36(1), 22-40 (2011).

    3. Suematsu, Y., Miura, S., Goto, M., et al. LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice. Eur. J. Heart Fail. 18(4), 386-393 (2016).

    4. Irons, B.K., Tsikouris, J.P., and Thomas, A.A. The use of angiostensin receptor blockers in the treatment of chronic hear failure. J. Cardiovasc. Pharmacol. 44(6), 718-724 (2004).

    5. Schiffrin, E.L. Beyond blood pressure: The endothelium and atherosclerosis progression. Am. J. Hypertens. 15(10 Pt 2), 115S-122S (2002).